Abstract
The objective: to evaluate the effectiveness of L-arginine in the correction of dysfunction in the utero-placental-fetal complex, intrauterine development of the fetus and the condition of the newborn in the early period of adaptation. Materials and methods. A prospective double-blind, randomized, multicenter controlled clinical trial was carried out at the Republican Specialized Scientific and Practical Medical Center of Obstetrics and Gynecology, II Clinic of the Tashkent Medical Academy and the Republican Perinatal Center of the Ministry of Health of the Republic of Uzbekistan. Results. Treatment with L-arginine in women at the end of the second and beginning of the third trimester of pregnancy with chronic diseases complicated by placental dysfunction improves perinatal outcomes, leads to a decrease in the number of premature births and asphyxiation of newborns. Conclusion. The use of L-arginine in the treatment of preeclampsia and correction of disorders in the utero-placental-fetal complex significantly improves the utero-placental-fetal blood flow. This allows to prolong the pregnancy to the optimal term of delivery. Key words: utero-placental-fetal blood flow, placental dysfunction, fetoplacental insufficiency, pregnant women, newborns, correction, therapy, L-arginine, Tivortin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
